Daniel Barber - 09 Mar 2026 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Reporting relationship: President and CEO
Issuer ticker: AQST
Reported as of: 09 Mar 2026
Net transaction value: -$753,965
SEC form: 4
Accepted by SEC: 11 Mar 2026, 12:52:40 UTC
Prior SEC filing: 29 Sep 2025
Next SEC filing: 07 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Lori Braender, as Attorney-In-Fact

Key filing fact

Daniel Barber filed Form 4 for Aquestive Therapeutics, Inc. (AQST) on 11 Mar 2026.

Key facts

This page summarizes Daniel Barber's Form 4 filing for Aquestive Therapeutics, Inc. (AQST).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Mar 2026, 12:52.

Change

Previous filing in this sequence was filed on 29 Sep 2025.
Current net transaction value: -$753,965.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001742266 Primary reporting owner

Barber Daniel

Relationship: President and CEO
Address: C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN
Signature: /s/ Lori Braender, as Attorney-In-Fact
Signature date: 11 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AQST transaction

Common Stock

Award

Transaction value
Shares: +262,000
Change %: +28%
Price: $0.000000^*
Shares after: 1,185,430
Date: 09 Mar 2026
Ownership: Direct
Footnotes: F1

AQST transaction

Common Stock

Sale

Transaction value: $753,965
Shares: -180,677
Change %: -15%
Price: $4.17
Shares after: 1,004,753
Date: 10 Mar 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AQST transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +523,000
Change %
Price: $4.29^*
Shares after: 523,000
Date: 09 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 523,000
Exercise price: $4.29
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Footnote F2

Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Footnote F3

This transaction was executed in multiple trades at prices ranging from $4.17 to $4.33. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Footnote F4

The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.